Relay Therapeutics is a clinical-stage precision medicines company. Co. has deployed its technology platform to build a pipeline of product candidates to address targets in precision medicine where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients for treatment. Co. has initiated a clinical trial for one of its product candidates, RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced or metastatic FGFR2-altered solid tumors. The U.S. Food and Drug Administration has granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma.